Targeting pathways with curcumin, such as MAPK/ERK, PI3k/AKT, Wnt/β-catenin, Notch, and MircoRNA, has been evaluated to improve osteosarcoma patient outcomes. The gene discussed is AKT1; the disease is osteosarcoma.